Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer (EROS)

Trial Profile

Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer (EROS)

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Oxaliplatin (Primary) ; Raltitrexed (Primary) ; Bevacizumab
  • Indications Colorectal cancer
  • Focus Pharmacokinetics
  • Acronyms EROS
  • Most Recent Events

    • 10 Apr 2017 Last checked against ClinicalTrials.gov record.
    • 13 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top